Hepion Pharmaceuticals Inc. [NASDAQ: HEPA] stock went on an upward path that rose over 5.88% on Thursday, amounting to a one-week price increase of more than 15.02%.
Over the last 12 months, HEPA stock rose by 19.21%. The average equity rating for HEPA stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $32.76 million, with 8.50 million shares outstanding and 6.07 million shares in the current float. Compared to the average trading volume of 1.68M shares, HEPA stock reached a trading volume of 1012266 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Hepion Pharmaceuticals Inc. [HEPA]:
ROTH Capital have made an estimate for Hepion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 20, 2020.
The Average True Range (ATR) for Hepion Pharmaceuticals Inc. is set at 0.27 The Price to Book ratio for the last quarter was 1.85, with the Price to Cash per share for the same quarter was set at 1.93.
HEPA Stock Performance Analysis:
Hepion Pharmaceuticals Inc. [HEPA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.02. With this latest performance, HEPA shares dropped by -3.23% in over the last four-week period, additionally plugging by 176.92% over the last 6 months – not to mention a rise of 19.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HEPA stock in for the last two-week period is set at 53.92, with the RSI for the last a single of trading hit 61.27, and the three-weeks RSI is set at 53.05 for Hepion Pharmaceuticals Inc. [HEPA]. The present Moving Average for the last 50 days of trading for this stock 3.71, while it was recorded at 3.34 for the last single week of trading, and 3.38 for the last 200 days.
Insight into Hepion Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for HEPA is now -76.15, given the latest momentum, and Return on Invested Capital for the company is -71.85. Return on Equity for this stock declined to -73.99, with Return on Assets sitting at -46.95. When it comes to the capital structure of this company, Hepion Pharmaceuticals Inc. [HEPA] has a Total Debt to Total Equity ratio set at 4.99. Additionally, HEPA Total Debt to Total Capital is recorded at 4.75, with Total Debt to Total Assets ending up at 3.95. Long-Term Debt to Equity for the company is recorded at 3.74, with the Long-Term Debt to Total Capital now at 3.18.
Reflecting on the efficiency of the workforce at the company, Hepion Pharmaceuticals Inc. [HEPA] managed to generate an average of -$559,891 per employee.Hepion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.00 and a Current Ratio set at 7.00.
HEPA Stock EPS
With the latest financial reports released by the company, Hepion Pharmaceuticals Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.64/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HEPA.
Hepion Pharmaceuticals Inc. [HEPA] Insider Position Details
There are presently around $1 million, or 3.60% of HEPA stock, in the hands of institutional investors. The top three institutional holders of HEPA stocks are: BLACKROCK INC. with ownership of 60,722, which is approximately 0% of the company’s market cap and around 1.64% of the total institutional ownership; PROSPERA FINANCIAL SERVICES INC, holding 33,800 shares of the stock with an approximate value of $0.12 million in HEPA stocks shares; and DIMENSIONAL FUND ADVISORS LP, currently with $0.12 million in HEPA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Hepion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of September and at the time of the September reporting period, where 6 institutional holders increased their position in Hepion Pharmaceuticals Inc. [NASDAQ:HEPA] by around 31,223 shares. Additionally, 6 investors decreased positions by around 96,168 shares, while 9 investors held positions by with 31,151 shares. The mentioned changes placed institutional holdings at 158,542 shares, according to the latest SEC report filing. HEPA stock had 5 new institutional investments in for a total of 30,223 shares, while 3 institutional investors sold positions of 94,331 shares during the same period.